Status:
TERMINATED
Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Medical Research Council
Royal Brompton & Harefield NHS Foundation Trust
Conditions:
Muscle Weakness
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-65 years
Brief Summary
Pulmonary arterial hypertension (PAH) is a disease that causes raised blood pressure in blood vessels that pick up oxygen from the lungs. It has a life expectancy similar to some cancers. There is tre...
Eligibility Criteria
Inclusion
- Patients with pulmonary arterial hypertension with New York Heart Association stage II - III disease will be eligible for recruitment in the patient portion of the trial. Interested healthy age matched volunteers will also be recruited.
Exclusion
- Patients and volunteers will be excluded if they have significant co-morbidities including other cardiorespiratory disease, metabolic abnormalities including diabetes or thyroid disorders. They will be excluded if they cannot safely exercise and perform a six minute walk test or if they are wheelchair bound.
Key Trial Info
Start Date :
October 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT01847716
Start Date
October 1 2013
End Date
August 1 2016
Last Update
September 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton Hospital
London, United Kingdom, SW36NP